Lucas Seibolt, MD
Interventional Cardiology · Valdosta, GANPI 1588074140
Payments from drug & device makers
Across 478 payments — averaging $77.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$24K
- Abbott$7K
- E.r. Squibb & Sons, L.L.C.$708
- Abiomed$679
- Novartis$628
- Boehringer Ingelheim$627
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 170 | $23,658 |
| Abbott | 14 | $6,519 |
| E.r. Squibb & Sons, L.L.C. | 47 | $708 |
| Abiomed | 13 | $679 |
| Novartis | 32 | $628 |
| Boehringer Ingelheim | 29 | $627 |
| Johnson & Johnson | 30 | $535 |
| AstraZeneca | 21 | $473 |
| Merck | 24 | $412 |
| Shockwave Medical, Inc | 10 | $347 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $303 |
| Medical Device Business Services, Inc. | 1 | $280 |
| Pfizer | 15 | $268 |
| Boston Scientific | 8 | $246 |
| Angiodynamics, Inc. | 1 | $166 |
| Amgen | 10 | $166 |
| Alnylam Pharmaceuticals Inc. | 6 | $153 |
| Edwards Lifesciences | 2 | $125 |
| Biosense Webster, Inc. | 7 | $119 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Bridgebio Pharma, Inc. | 3 | $57 |
| Atricure, Inc. | 2 | $55 |
| Kestra Medical Technology Services, Inc. | 3 | $53 |
| Lantheus Medical Imaging, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Inari Medical, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Cleerly, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Asahi Intecc USA, Inc. | 1 | $14 |
How this compares
$36,829 in reported general payments places this provider in the 70th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Valdosta
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Amar PatelMarietta$1.8M
- Vivek RajagopalAtlanta$1.3M
- Christopher MeduriAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.